Taurine Should Not Be Added to This Heart Failure Regimen
Taurine is not recommended as an addition to guideline-directed medical therapy (GDMT) for heart failure, as it lacks evidence from high-quality clinical trials demonstrating mortality or morbidity benefit, and established evidence-based therapies should be prioritized and optimized instead.
Guideline-Directed Medical Therapy Takes Priority
The current evidence-based approach to heart failure management emphasizes a structured pharmacological foundation that has proven mortality and morbidity benefits:
ACE inhibitors (or ARBs like losartan) combined with beta-blockers (carvedilol) form the cornerstone of HFrEF treatment, with Class I, Level A evidence for reducing hospitalization and death 1.
Mineralocorticoid receptor antagonists (MRAs) are recommended for patients who remain symptomatic despite ACE inhibitor and beta-blocker therapy to further reduce the risk of HF hospitalization and death (Class I, Level A) 1.
The patient described is already on losartan (an ARB) and carvedilol (a beta-blocker), but notably missing an MRA from the regimen 2.
Why Taurine Is Not Recommended
Lack of High-Quality Clinical Evidence
Taurine has only mechanistic and preclinical data supporting its use in heart failure, with one older review from 2000 discussing theoretical mechanisms including natriuresis, modest positive inotropy, and attenuation of angiotensin II effects 3.
No randomized controlled trials have demonstrated that taurine reduces mortality, hospitalizations, or improves quality of life in heart failure patients 3.
The 2000 review itself acknowledges that "it remains to be determined whether taurine treatment promotes salt and water excretion in humans with heart failure" and that taurine's effects "have not been examined in human tissue" 3.
Guidelines Do Not Include Taurine
Neither the 2016 ESC guidelines 1, the 2022 AHA/ACC/HFSA guidelines 4, nor any European guidelines 2, 5, 6, 5 mention taurine as a recommended therapy for heart failure.
The most recent 2024 and 2025 updates on heart failure management focus on SGLT2 inhibitors, finerenone, semaglutide for HFpEF with obesity, and optimization of quadruple therapy—not nutritional supplements like taurine 7, 8.
What Should Be Done Instead
Optimize Evidence-Based Therapy First
Before considering any unproven therapies, the patient's current regimen should be evaluated and optimized:
Consider adding an MRA (spironolactone or eplerenone) if the patient has symptomatic HFrEF (NYHA Class II-IV), as this is a Class I recommendation with proven mortality benefit 5, 1, 5, 1, 5.
Even with eGFR ≥30 mL/min/1.73 m², MRAs remain beneficial and safe when appropriately monitored, with significant absolute risk reduction in high-risk patients 9.
Ensure target dosing of current medications: The evidence strongly supports uptitration to target doses used in clinical trials rather than settling for medium-range doses, as higher doses provide greater survival benefits 10.
Consider Sacubitril/Valsartan
Sacubitril/valsartan is recommended as a replacement for ACE inhibitors or ARBs to further reduce HF hospitalization and death in ambulatory patients with HFrEF who remain symptomatic despite optimal therapy (Class I, Level B) 1.
ARNI prescription rates have increased dramatically, reaching 55.4% by late 2022 in eligible hospitalized patients, reflecting growing recognition of its benefits 11.
Add SGLT2 Inhibitors
- SGLT2 inhibitors are now recommended across the entire left ventricular ejection fraction spectrum and represent a major advance in HF therapy 7, 8.
Common Pitfalls to Avoid
Do not add unproven supplements when evidence-based therapies are not yet optimized: The patient's LDL is already at 45 mg/dL on rosuvastatin, indicating good lipid control, but the HF regimen may not be maximized 12.
Do not assume that "natural" or "nutritional" therapies are harmless additions: Without clinical trial data, the risk-benefit profile of taurine in this specific patient population remains unknown 3.
Avoid the clinical practice pattern of undertreating with low doses: Physicians often fail to uptitrate to target doses due to unfounded fears about tolerability, but this represents a missed opportunity for mortality reduction 10.